[US-헬스케어] 05/14 Wall St. Recap

Eli Lilly (LLY) continues to demonstrate a robust long-term growth strategy, balancing its dominant position in the (GLP-1) obesity market with aggressive expansion into oncology. The recent Q1 earnings beat underscores the company’s operational strength, while the strategic $7 billion investment in (Cancer Therapeutics) and potential acquisition of (Kelonia Therapeutics) signal a clear intent to diversify its pipeline beyond metabolic diseases. While short-term price volatility is evident, the focus on developing (Oral Obesity Drugs) remains the critical catalyst for maintaining market leadership and sustaining valuation premiums through 2026.

Novo Nordisk (NVO) is demonstrating a robust recovery trajectory in 2026, primarily driven by the superior performance of its oral GLP-1 (Wegovy Pill), which has significantly outperformed market expectations. The recent price appreciation reflects a market recalibration as investors digest the company’s ability to scale production and maintain its competitive moat in the obesity care market.

While the stock experienced a substantial drawdown from its previous highs, the current valuation presents a compelling entry point for long-term investors. Furthermore, the strategic dynamics within the sector—highlighted by the competitive tension with players like Hims & Hers—underscore Novo Nordisk’s dominant position as the industry benchmark. The company’s ability to pivot toward more convenient oral delivery formats is a critical catalyst for sustained margin expansion and market share retention.

Amgen (AMGN) is currently at a critical juncture as it balances recent capital expenditure with market volatility ahead of its earnings release. The company’s decision to invest an additional $300 million in domestic manufacturing capacity underscores a long-term commitment to supply chain resilience and operational scaling. However, the recent 6% pre-earnings pullback reflects investor anxiety regarding margin pressure and the sustainability of its recent valuation premium. While the stock’s DCF (Discounted Cash Flow) profile suggests underlying value, the market is clearly waiting for concrete evidence of pipeline execution and revenue growth to justify further upside after a strong 12-month run. Investors should monitor whether these infrastructure investments will drive long-term competitive moats or if short-term capital intensity will weigh on near-term profitability.

분석 지연 중.

분석 지연 중.